Skip to contentSkip to filters

We use cookies for analytics.

FDA Grand Rounds – Statistical Considerations for Drug Development in Rare Disease

Emily Morris, PhD

Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Recording

50 min

Abstract

Small patient populations leave researchers with limited information when planning a phase III rare disease trial. Emily Morris discusses statistical choices in trial design and how adaptive designs can address uncertainty in the available evidence.

Topics